Sumitomo Pharma Co., Ltd.
Quick facts
| Founded | 1897 |
|---|
Phase 3 pipeline
- Amrubicin hydrocloride · Oncology
Amrubicin is a topoisomerase II inhibitor that intercalates into DNA and prevents the religation of DNA strands, leading to cell death. - DSP-5423P Active-to-Flex · Neurology/Psychiatry
DSP-5423P is a selective dopamine D1 receptor partial agonist designed to modulate dopaminergic signaling in the central nervous system. - DSP-5423P Placebo-to-Flex
DSP-5423P Placebo-to-Flex's mechanism of action is currently unknown. - ranirestat, (AS-3201) · Endocrinology / Diabetes
Ranirestat inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications. - SM-13496 · Diabetes
SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). - SM-13496 (lurasidone HCl) · Psychiatry
SM-13496 (lurasidone HCl) is an atypical antipsychotic that acts as a serotonin 2A receptor antagonist and a dopamine receptor antagonist.
Phase 2 pipeline
- DSP-3025
- DSP-7888
DSP-7888 is a cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Sumitomo Pharma Co., Ltd.
What is Sumitomo Pharma Co., Ltd.'s pipeline?
Sumitomo Pharma Co., Ltd. has 6 drugs in Phase 3, 2 in Phase 2, 3 in Phase 1. Late-stage candidates include Amrubicin hydrocloride, DSP-5423P Active-to-Flex, DSP-5423P Placebo-to-Flex, ranirestat, (AS-3201).
When was Sumitomo Pharma Co., Ltd. founded?
Sumitomo Pharma Co., Ltd. was founded in 1897.
Related
- Sector hub: All tracked pharma companies